Immunicum AB (IMMU) - Financial Analysis Review

Summary

Immunicum AB (Immunicum) is a biopharmaceutical company that develops therapeutic for treatment of cancer. The companys products comprise INTUVAX-RCC, INTUVAX-HCC, SUBCUVAX and CD70. Immunicums CD70 is in a preclinical phase studies. It has partnerships with biotech and pharmaceutical companies, INTUVAX-RCC is a drug candidate used to treat Renal cell carcinoma, INTUVAX-HCC is used for treating liver cancer and SUBCUVAX is a drug candidate, which induces a tumor specific immune reaction in vitro. The company uses technologies such as COMBIG and CD70 to develop therapeutic cancer vaccines. Immunicum is headquartered in Gothenburg, Sweden

GlobalData's Immunicum AB (IMMU) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Immunicum AB Key Recent Developments:

Sep 27,2016: Immunicum Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development
Sep 14,2016: Immunicum Announces that a Patent Application in the USA Regarding the Company's CD70-Technology will be Granted
Jul 22,2016: Immunicum Announces Appointment of Chief Medical Officer, Peter Suenaert, M.D., Ph.D.
May 02,2016: Immunicum applies for listing on the Nasdaq Stockholm main market
Mar 03,2016: Immunicum announces new member of the Scientific Advisory Board Anders Ohlen, further expanding the industrial experience and expertise in clinical development


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends,